Although the first phase 3 trial of anifrolumab did not meet its primary end point, other study end points that were met suggested a clinical benefit for the monoclonal antibody in systemic lupus erythematosus.
Researchers addressed the association between cardiovascular risk and glucocorticoids in patients with systemic lupus erythematosus.
Researchers compared the rate of opioid overdose-related hospitalizations among patients with systemic lupus erythematosus and rheumatoid arthritis vs the general population.
Researchers examined the association of blood levels of hydroxychloroquine with thrombotic events in a longitudinal systemic lupus erythematous cohort.
Researchers studied cancer risk in patients with systemic lupus erythematosus and identified specific risk factors.
The FDA has granted Breakthrough Therapy designation to obinutuzumab (Genentech), a CD20-directed cytolytic antibody, for the treatment of adults with lupus nephritis.
Researchers analyzed the clinical features and outcomes of infections in the central nervous system (CNS) in patients with systemic lupus erythematosus (SLE) and created a simplified scoring system to differentiate CNS infections from neuropsychiatric SLE.
This study reports the long-term renal outcomes of kidney biopsies performed at prespecified intervals to determine the safety and accuracy of tapering of maintenance immunosuppression.
New 2019 classification criteria for systemic lupus erythematosus was jointly developed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).
AstraZeneca has announced positive topline data from the phase 3 TULIP 2 trial of anifrolumab for the treatment of systemic lupus erythematosus.